Merck & Company, Inc. vs Zimmer Biomet Holdings, Inc. — Stock Comparison
Merck & Company, Inc. (MRK) and Zimmer Biomet Holdings, Inc. (ZBH) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Merck & Company, Inc. and Zimmer Biomet Holdings, Inc. are evenly matched on Q·Score (7/10 each). Zimmer Biomet Holdings, Inc. scores higher on Growth, reflecting stronger revenue and earnings momentum. Analyst price targets imply similar upside for both: +12.4% for MRK and +13.2% for ZBH.
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 19% return on equity and 14% profit margins.
Earnings growing 34% year-over-year on 9% revenue growth.
⚠ cautious analyst consensus — few Buy ratings.
Analyst Consensus
Fundamentals
Frequently Asked Questions
MRK vs ZBH: which stock scores better overall?
Based on Q·Score, Merck & Company, Inc. (MRK) scores 7/10 versus Zimmer Biomet Holdings, Inc. (ZBH) at 7/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: MRK or ZBH?
Zimmer Biomet Holdings, Inc. (ZBH) scores higher on Growth (8.8/10 vs 6.2/10). Merck & Company, Inc. reports revenue growth (4.9% YoY) while Zimmer Biomet Holdings, Inc. reports (9.3% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is MRK or ZBH more attractively valued?
Zimmer Biomet Holdings, Inc. (ZBH) scores higher on Valuation (7.2/10 vs 6.7/10). MRK trades at 12.1× P/E versus ZBH at 9.7×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about MRK vs ZBH?
There are 27 analysts covering MRK with a consensus price target of $129.74, and 20 analysts covering ZBH with a consensus target of $98.70. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: MRK or ZBH?
Merck & Company, Inc. (MRK) scores higher on Quality (7.7/10 vs 6/10). Net profit margin: MRK at 13.6%, ZBH at 9.1%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: MRK or ZBH?
Zimmer Biomet Holdings, Inc. (ZBH) scores higher on Financial Health (7.6/10 vs 7/10). Market beta: MRK at 0.22, ZBH at 0.47. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of MRK and ZBH?
Merck & Company, Inc. (MRK) has a market capitalisation of $285.1B, while Zimmer Biomet Holdings, Inc. (ZBH) has a market cap of $16.9B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do MRK or ZBH pay dividends?
MRK pays a dividend yield of 2.95%, while ZBH pays a dividend yield of 1.07%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →